Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Darren K. McGuire, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, David Fitchett, Stefan D. Anker, Stuart Pocock, Stefan Kaspers, Jyothis T. George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, U Elsasser, Stefan Hantel, Søren S. Lund
Topics & Concepts
EmpagliflozinMedicineInternal medicineMyocardial infarctionPlaceboDiabetes mellitusType 2 diabetesClinical trialAdverse effectHazard ratioCardiologyConfidence intervalEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsMetabolism, Diabetes, and Cancer